About Intraflagellar transport protein 20 homolog
Intraflagellar transport protein 20 homolog (IFT20) is a protein
from Homo sapiens identified by UniProt accession
Q8IY31, 132 residues long.
MolForge cross-references it against 0 known binders and
49 disease associations.
Target properties
| Protein name | Intraflagellar transport protein 20 homolog |
|---|
| UniProt accession | Q8IY31 |
|---|
| Gene | IFT20 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 132 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (49)
Diseases linked to this target (Open Targets).
- vascular endothelial growth factor A measurement · score 0.07
- non-receptor tyrosine-protein kinase TYK2 measurement · score 0.07
- breast cancer anti-estrogen resistance protein 3 measurement · score 0.07
- serine/threonine-protein kinase 17B measurement · score 0.07
- Abelson tyrosine-protein kinase 2 measurement · score 0.07
- macrophage scavenger receptor types I and II measurement · score 0.07
- OCIA domain-containing protein 1 measurement · score 0.07
- neoplasm · score 0.06
- sporadic amyotrophic lateral sclerosis · score 0.06
- blood protein measurement · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8IY31-F1 | alphafold | PREDICTED | 94.51 | — |
Amino-acid sequence (132 residues)
MAKDILGEAG LHFDELNKLR VLDPEVTQQT IELKEECKDF VDKIGQFQKI VGGLIELVDQ LAKEAENEKM KAIGARNLLK SIAKQREAQQ QQLQALIAEK KMQLERYRVE YEALCKVEAE QNEFIDQFIF QK
Explore Intraflagellar transport protein 20 homolog with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets